Single brand, fully-covered, self-expandable metal stent for the treatment of benign biliary disease: when should stents be removed?
| Autor: | Rinaldo Pellicano, Benedetto Mangiavillano, Alessandro Repici, Ilaria Tarantino, Leonardo Henry Eusebi, Rossella Semeraro, Mouen A. Khashab, Mario Traina, Mario Bianchetti |
|---|---|
| Přispěvatelé: | Mangiavillano, Benedetto, Khashab, Mouen A, Eusebi, Leonardo H, Tarantino, Ilaria, Bianchetti, Mario, Semeraro, Rossella, Pellicano, Rinaldo, Traina, Mario, Repici, Alessandro |
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Cholestasis Nutrition and Dietetics High interest business.industry Self expandable biliary stent biliary diseases Biliary Tract Diseases Endocrinology Diabetes and Metabolism medicine.medical_treatment Gallbladder disease Gastroenterology Stent medicine.disease Surgery Biliary disease High morbidity Stent removal Internal Medicine Balloon dilation Humans Medicine Stents Endoscopy Digestive System business |
| Zdroj: | Minerva Gastroenterologica e Dietologica. 65 |
| ISSN: | 1827-1642 1121-421X |
| Popis: | The two most relevant endoscopic treatable benign biliary diseases (BBD) are benign biliary strictures (BBSs) and biliary leaks (BLs), often associated with high morbidity. The most common endoscopic treatment for biliary strictures involves placement of multiple plastic stents (PSs), with or without balloon dilation, followed by planned exchange of the stents. Thus, there continues to be high interest in pursuing alternative endoscopic approaches that may achieve better results with fewer interventions. In this setting, the use of a fully-covered, self-expandable metal stent (FCSEMS) is an attractive alternative to single or multiple PSs for the treatment of BBDs. A single metal stent can remain in place for a longer period of time before removal; however, the maximum time the stent can be remain in place is still not well defined. The aim of this review is to determine the removal time of the TaeWoong® FCSEMS, placed for BBD. According to our data analysis, considering the absence of loss of the covering of the FCSEMS and of any adverse events during and after stent removal, leaving the TaeWoong medical FCSEMS in situ for an 8 months' period seems to be acceptable for benign biliary diseases. Further studies need to evaluate their removability at 1 year. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|